Don't miss real-time top news, insights, and interviews with the experts direct from the conference floor in Chicago. Sign up now to be reminded to tune in to OncLive News Network: On Location in Chicago.

Understanding the Adverse Events of PARP Inhibitors

BOBBIE J. RIMEL, MD
Saturday, February 23, 2019


There are three adverse events (AEs) that are common to all the PARP inhibitors used to treat ovarian cancer: fatigue, anemia, and nausea, explained Bobbie J. Rimel, MD, an assistant professor of obstetrics and gynecology at Cedars-Sinai.

However, there are also AEs that tend to be more common for certain agents. For example, niraparib (Zejula) is more likely to cause high blood pressure; rucaparib (Rubraca) is more likely to affect kidney function; and olaparib (Lynparza) is more likely to cause gastrointestinal issues.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Videos
By: Raymond Chan, PhD, RN, BN, MAppSc
By: Grace Campbell, PhD, MSW, RN, CNL, CRRN
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2018
Intellisphere, LLC. All Rights Reserved.